Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics Inc (NQ: STOK )

14.40 +0.07 (+0.52%)
Streaming Delayed Price Updated: 9:53 AM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,249
Open 14.29
Bid (Size) 14.35 (2)
Ask (Size) 14.46 (3)
Prev. Close 14.33
Today's Range 14.29 - 14.55
52wk Range 3.350 - 17.58
Shares Outstanding 44,188,534
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
Via Benzinga
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire

Performance

YTD
+145.82%
+145.82%
1 Month
+2.42%
+2.42%
3 Month
+121.62%
+121.62%
6 Month
+173.86%
+173.86%
1 Year
+38.05%
+38.05%

More News

Read More
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Analyst Expectations For Stoke Therapeutics's Future
Via Benzinga
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
From Stoke Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
From Stoke Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
What's Going On With Stoke Therapeutics Stock Tuesday?
Via Benzinga
Stoke Therapeutics Announces Proposed Public Offering
From Stoke Therapeutics, Inc.
Via Business Wire
Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Gains 100 Points; McCormick Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Stoke Therapeutics Inc. (NASDAQ: STOK) Near the Top of Equities by Percentage Gain on 3/26
Via Investor Brand Network
Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February
Via Benzinga
Topics Stocks
Exposures US Equities
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
Via Benzinga
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.